Quick Takeaways
- This page summarizes Anthony Hunt's Form 4 filing for REPLIGEN CORP (RGEN).
- 10 reported transactions and 2 derivative rows are listed below.
- Filing timestamp: 19 Mar 2025, 16:21.
Anthony Hunt - 17 Mar 2025 Form 4 Insider Report for REPLIGEN CORP (RGEN)
- Role
- Director
- Signature
- /s/ Marc Baumgartner (Attorney in Fact)
- Issuer symbol
- RGEN
- Transactions as of
- 17 Mar 2025
- Net transactions value
- -$2,616,396
- Form type
- 4
- Filing time
- 19 Mar 2025, 16:21:04 UTC
- Previous filing
- 04 Mar 2025
- Next filing
- 20 Mar 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Anthony Hunt filed Form 4 for REPLIGEN CORP (RGEN) on 19 Mar 2025."
What Changed
- Previous filing in this sequence was filed on 04 Mar 2025.
- Current net transaction value: -$2,616,396.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RGEN | Common Stock | Options Exercise | $169,350 | +5,000 | +3.7% | $33.87 | 141,301 | 17 Mar 2025 | Direct | |
| transaction | RGEN | Common Stock | Options Exercise | $1,294,917 | +21,756 | +15% | $59.52 | 163,057 | 17 Mar 2025 | Direct | |
| transaction | RGEN | Common Stock | Sale | $8,883 | -60 | -0.04% | $148.05 | 162,997 | 17 Mar 2025 | Direct | F1, F2 |
| transaction | RGEN | Common Stock | Sale | $15,038 | -100 | -0.06% | $150.38 | 162,897 | 17 Mar 2025 | Direct | F1 |
| transaction | RGEN | Common Stock | Sale | $380,445 | -2,518 | -1.5% | $151.09 | 160,379 | 17 Mar 2025 | Direct | F1, F3 |
| transaction | RGEN | Common Stock | Sale | $938,505 | -6,176 | -3.9% | $151.96 | 154,203 | 17 Mar 2025 | Direct | F1, F4 |
| transaction | RGEN | Common Stock | Sale | $2,386,896 | -15,619 | -10% | $152.82 | 138,584 | 17 Mar 2025 | Direct | F1, F5 |
| transaction | RGEN | Common Stock | Sale | $350,897 | -2,283 | -1.6% | $153.70 | 136,301 | 17 Mar 2025 | Direct | F1, F6 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RGEN | Stock Option (Right to Buy) | Options Exercise | $0 | -5,000 | -2.4% | $0.000000 | 202,344 | 17 Mar 2025 | Common Stock | 5,000 | $33.87 | Direct | F7 |
| transaction | RGEN | Stock Option (Right to Buy) | Options Exercise | $0 | -21,756 | -100% | $0.000000 | 0 | 17 Mar 2025 | Common Stock | 21,756 | $59.52 | Direct | F8 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. |
| F2 | $148.05 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.01 to $148.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| F3 | $151.09 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.42 to $151.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| F4 | $151.96 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.43 to $152.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| F5 | $152.82 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.39 to $153.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range |
| F6 | $153.70 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.55 to $153.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| F7 | 207,344 of the shares underlying this option have vested. The remaining shares vest as follows: 28,777 shares on March 1, 2026, and 28,778 shares on March 1, 2027. |
| F8 | This option is fully vested and exercisable. |